Логотип

        
    Поиск:   

Вместе мы можем:

Сказать прививкам — «Нет!»

Участвовать в жизни организации >>

Общаться на нашем форуме >>

Помочь проекту материально:
WebMoney — R419388931697
Яндекс-деньги — 410011298069472

Мы в Твиттере



Техническая поддержка
CYGNUS HOSTING

Версия для печати

Календарь прививок Канады, 2013 год

Финансируемые государством программы иммунизации в Канаде - обычный график для младенцев и детей, в том числе специальные программы и догоняющие программы, по провинциям / территориям
(по состоянию на сентябрь 2013 года)


Финансируемые государством программы иммунизации для лиц высокой степени риска, по провинциям / территориям  (по состоянию на сентябрь 2013 года)

Государственное финансирование вакцинации против гриппа по провинциям / территориям
(по состоянию на сентябрь 2013 года)


Вакцинация конкретных групп населения
  
Иммунизация взрослых

      Рекомендации по иммунизации взрослых людей для конкретных ситуаций риска
      Резюме рекомендаций для иммунизации восприимчивых беременных женщин или кормящих матерей


 
http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php

Финансируемые государством программы иммунизации в Канаде - обычный график для младенцев и детей, в том числе специальные программы и догоняющие программы
(по состоянию на сентябрь 2013 года)

Обычный график для младенцев и детей

Провинция или территория DTaP-IPV-Hib DTaP-IPV Tdap or Tdap-IPV HB MMR Var MMR-Var Men-C Men-C-A, C, Y, W-135 Pneu-
C-13
Inf HPV Rot
Legend:
DTaP: Diphtheria, Tetanus, Acellular PertussisHB:Hepatitis B
Hib: Haemophilus Influenzae Type b
HPV: Human Papillomavirus
Inf: Influenza
IPV: Inactivated Poliomyelitis
Men-C: Meningococcal conjugate
MMR: Measles, Mumps, Rubella
MMRV: Measles, Mumps, Rubella, and Varicella
Pneu-C-13: Pneumococcal conjugate 13 valent
PP23 : Pneumococcal polysaccharide 23 valent
Rot: Rotavirus
Tdap: Tetanus, Diptheria, Acelluar Pertussis
Var: Varicella
HR: Children at high risk only (Definitions of High Risk for Publicly-funded Vaccines by Province/Territory)
Source: Canadian Nurses Coalition on Immunization, 2013

Recommended use:

  1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations (PDF Document - 712 Kb - 40 pages)
  2. The HPV vaccine is recommended for females (HPV2 or HPV4) and males (HPV4) between 9 and 26 years of age.
    Update On Human Papillomavirus (HPV) Vaccines
NACI recom-
mendation
2, 4, 6, 18 mths 4-6 yrs 14-16 yrs Infancy (3 doses) OR Pre-teen/
teen (2-3 doses)
12 mths
AND 18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12-18 mths
AND
18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12 mths AND 18 mths OR 4-6 yrs Infancy (1-4 doses)1 AND Pre-teen (1 dose)1 Pre-teen (1 dose)1 2, 4, 6, 12-15 mths 6-59 mths (1-2 doses) 9-18 yrs
(3 doses at 0, 2, 6 mths)2
2, 4, 6 mths
BC 2, 4, 6 (DTaP- HB-IPV-Hib), 18 mths (DTaP-IPV-Hib) 4-6 yrs Tdap, Gr. 9 2, 4, 6 mths (DTaP- HB-IPV-Hib) 12 mths,
4-6 yrs
12 mths, 4-6 yrs;
Catch-up;
Gr. 6
  2, (4 HR), 12 mths,
Gr. 6
  2, 4, (6 HR), 12 mths 6-59 mths Females
Gr. 6
2, 4 mths
AB 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 Gr. 5     12 mths, 4-6 yrs 2, 4, 12 mths Grade 9 (1 dose) 2, 4, (6 HR), 12 mths ≥ 6 mths Females Gr. 5  
SK 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 8 Gr. 6 Catch-up Gr. 6, 8 until Aug 2013 Catch-up Gr. 6 until Aug. 2015 12, 18 mths 12 mths Gr. 6 2, 4, (6 HR), 12 mths ≥ 6 mths Females Gr. 6 2, 4 mths
MB 2, 4, 6, 18 mths 4-6 yrs Tdap, 14-16 yrs Gr. 4 4-6 yrs   12 mths 12 mths, Gr. 4 until 2017   2, 4, (6 HR), 12 mths 2012-13 ≥ 6 mths Females Gr. 6; Catch-up ≤ Gr. 10 in 2012-13  
ON 2, 4, 6, 18 mths   Tdap-IPV 4-6 yrs, Tdap 14-16 yrs Gr. 7 12 mths 15 mths 4-6 yrs 12 mths Gr. 7 2, 4, (6 HR), 12 mths ≥ 6 mths Females Gr. 8 2, 4 mths
QC 2, 4, 18 (DTaP- HB-IPV-Hib), 6 mths (DTaP-IPV-Hib)   Tdap-IPV 4-6 yrs, Tdap 3rd year of high school 2, 4, 18 (DTaP- HB-IPV-Hib), Gr. 4 12 mths   18 mths 12 mths, 3rd year of high school; Catch-up < 18 yrs   2, 4, 12 mths  6-23 mths Females
Gr. 4; Catch-up Females < 18 yrs
2, 4 mths
NB 2, 4, 6, 18 mths 4 yrs (DTaP-IPV or Tdap-IPV) Tdap, Gr. 7 Tdap-IPV, 4 yrs (currently in place but will switch over to DTaP-IPV) 0, 2, 6 mths   One dose children born between 2000 and 2008; Catch-up 2 doses children born in 2009 or later 12, 18 mths 12 mths Gr. 9 2, 4, 12 mths 6 mths – 18 yrs Females Gr. 7  
NS 2, 4, 6, 18 mths   Tdap-IPV 4-6 yrs, Tdap Gr. 7 Gr. 7     12 mths, 4-6 yrs 12 mths, Gr. 7   2, 4, 12 mths ≥ 6 mths Females Gr. 7  
PE 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 2, 4, 18 mths     12, 18 mths 12 mths Gr. 9 2, 4, (6 HR), 18 mths 6-59 mths Females Gr. 6 2, 4 mths
NL 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 Gr. 6 18 mths   12 mths 12 mths Gr. 4 2, 4, 12 mths 6-59 mths Females Gr. 6  
NT 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 0, 1, 6 mths; Catch-up Gr.9 12, 18 mths, Post secondary students attending schools outside NT 12 mths; Catch-up <5 yrs, Gr.9   2, 12 mths; Catch-up < 5 yrs, Gr. 9 Post secondary students attending schools outside NT 2, 4, 6, 18 mths ≥ 6 mths Females Gr. 4; Catch-up Gr. 9-12 2009-14 2, 4 mths (to be introduced late Fall 2013)
YT 2, 4, 6 (DTaP-HB-IPV-Hib), 18 mths (DTaP-IPV-Hib) 4-6 yrs (DTaP-IPV or Tdap-IPV) Tdap, Gr. 9 2, 4, 6 mths (DTaP-HB-IPV-Hib); Catch-up ≤ 19 yrs 12 mths, 4-6 yrs 12 mths, 4-6 yrs   2, 12 mths; Gr. 6, post-secondary students not previously immunized   2, 4, (6 HR), 12 mths
(3 doses)
> 6mths Females
Gr. 6
2, 4 mths
NU 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 (14-16 yrs) 0, 1, 9 mths 12, 18 mths; Catch-up Gr. 12 15 mths   12 mths; Catch-up Gr. 9 (14-16 yrs)   2, 4, 6, 15 mths, plus PP23 (1 dose) 2-3 yrs Universal ≥ 6 mths Females Gr. 6 (≥ 9 yrs)  

http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-5-eng.php

Финансируемые государством программы иммунизации для лиц высокой степени риска
 (по состоянию на сентябрь 2013 года)
Провинция или территория Conjugated Pneumococcal Conjugated Meningococcal Group C Conjugated Meningococcal Groups A, C, Y, W-135 Varicella Human Papillomavirus

Source: Canadian Nurses Coalition on Immunization, 2013

BC

Children 2-59 mths of age who are at high risk of pneumococcal disease due to:

  • Sickle cell disease
  • Immunosuppression related to disease (e.g. HIV, lymphoma, Hodgkin’s, multiple myeloma) or therapy (e.g. high dose, systemic steroids or severe rheumatoid arthritis requiring immunosuppressive therapy)
  • Congenital immunodeficiencies
  • Receipt of hematopoietic stem cell transplant (HSCT).
  • Solid organ or islet cell transplant (candidate or recipient)
  • Chronic heart or lung disease (except asthma, unless management involves ongoing high dose oral corticosteroid therapy.)
  • Chronic liver disease including cirrhosis, chronic hepatitis B, chronic hepatitis C.
  • Chronic kidney disease
  • Diabetes
  • Cystic fibrosis
  • Chronic CSF leak
  • Cochlear implant, candidate or recipient
  • Anatomic or functional asplenia (children up to and including 16 years of age)
  • Chronic neurological conditions that may impair clearance of oral secretions

Children 2-10 years of age who have not previously received meningococcal C conjugate who have:

  • Functional or anatomic asplenia
  • Congenital immunodeficiency states including complement, properdin, factor D , and primary antibody deficiencies
  • Hematopoietic stem cell transplant (HSCT)
  • Solid organ transplant (candidate or recipient)
  • Islet cell transplant (candidate or recipient)
  • Close contacts of a case of invasive meningococcal group C disease

Individuals ≥ 2 years of age with the following conditions:

  • Functional or anatomic asplenia
  • Congenital immunodeficiency states including complement, properdin, factor D, and primary antibody deficiencies
  • Hematopoietic Stem Cell Transplant
  • Solid organ transplant (candidate or recipient)
  • Islet cell transplant (candidate or recipient)
  • High risk ≥ 2 years, and contacts (≥ 2 year) of cases (serotypes A, Y and W-135)

(1) Susceptible high risk persons:

  • With cystic fibrosis
  • With nephrotic syndrome
  • Undergoing hemo- or > peritoneal dialysis
  • On chronic salicylate therapy

(2) Children and adults with :

  • IG deficiency
  • Neutrophil deficiency
  • Complement deficiency
  • Asplenia
  • Receiving inhaled or topical > steroids
  • Child and adult candidates > for solid organ transplant> (liver, heart, lung, kidney).

(3) Children:

  • With acute lymphocytic > leukemia in remission for> at least 12 months
  • With asymptomatic HIV, > CD4% ³ 25% for age
  • ≥ 2 years after HSCT or> solid organ transplant
  • ≥ 3 months after being> cured of a malignant > disease and the end of immunosuppressive> treatment
 

AB

2 months to ≤ 5 years of age:

  • Aboriginal children (including First Nations, Inuit and Metis)
  • Cochlear implants (candidates and recipients)
  • Congenital or acquired asplenia, splenic dysfunction and sickle-cell disease
  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV infection
  • Immunosuppression (e.g., congenital immune deficiency, Hodgkin’s disease, lymphoma, multiple myeloma, leukemia and therapy with alkylating agents, antimetabolites, systemic corticosteroids or radiation therapy)
  • Chronic renal disease, including nephrotic syndrome
  • Chronic cardiac disease
  • Chronic pulmonary disease (excluding asthma unless treated with high-dose oral corticosteroid therapy)
  • Cerebrospinal fluid leaks
  • Poorly controlled diabetes mellitus
  • Chronic neurologic condition that may impair clearance of oral secretions.
  • Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humeral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions.
  • Chronic liver disease (including hepatitis B and C, and hepatic cirrhosis due to any cause).

6 to ≤ 16 years of age:

  • Congenital or acquired asplenia, including those with sickle-cell disease and other hemoglobinopathies (functional asplenia) and splenic dysfunction
  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV Infection

17 years and older:

  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV Infection

Pre-exposure:

Children at high risk 5 to 10 years of age inclusive who have not received meningococcal conjugate monovalent C vaccine previously. Children at high risk include those with the following conditions:

  • Candidates and recipients of cochlear implant surgery
  • Anatomical or functional asplenia (including sickle-cell disease)
  • HIV without any contraindications to immunization
  • Complement, properdin or factor D deficiency; hypogammaglobulinemia and primary antibody deficiency
  • Candidates and recipients of solid organ transplant- - Recipients of hematopoietic stem cell transplant

Post-exposure 2 to 23 months of age and 56 years of age and older:

Susceptible household and close contacts of laboratory-confirmed cases of serogroup C invasive meningococcal disease that are eligible for chemoprophylaxis and have not been adequately immunized. Results of index case serogrouping should be known (generally within 2 to 5 days) before proceeding with immunization.

Pre-exposure:

  • Laboratory workers who are routinely exposed to Neisseria meningitidis, if they are involved in conducting subculture identification, susceptibility testing, serological and/or molecular characterization and deep freeze for storage.
  • Candidates and recipients of cochlear implant surgery
  • Individuals with anatomical or functional asplenia (including sickle-cell disease)
  • Candidates and recipients of solid organ transplant
  • Recipients of hematopoietic stem cell transplant
  • Individuals who are HIV positive with no contraindication to immunization
  • Individuals with complement, properdin or factor D deficiency or hypogammaglobulinemia

Post-exposure:

Susceptible household and close contacts, 2 years of age and older, of laboratory-confirmed cases of serogroups A, Y or W-135 invasive meningococcal disease

Non-immune:

  • Household or close contacts of immunocompromised individuals
  • Susceptible health care workers
  • Women identified through routine prenatal screening
  • Individuals 13 years and older if susceptible (unknown, no or uncertain history of chickenpox and negative serology)
  • Immunocompromised individuals (medical consultation should be sought before)

Females students eligible for vaccine in Gr. 5 continue to be eligible until the end of Gr. 12 if they present to public health

SK

High risk groups 5-17 years include:

  • Sickle cell disease, congenital or acquired asplenia, or splenic dysfunction
  • Human immunodeficiency > virus (HIV) infection
  • Congenital immune deficiency
  • Diseases associated with immunosuppressive therapy or radiation therapy including > malignant neoplasms, leukemias, lymphomas, Hodgkin’s disease > and solid organ transplantation > or stem cell transplants
  • Chronic cardiac disease > (particularly cyanotic congenital> heart disease and cardiac failure)
  • Chronic pulmonary disease > (excluding asthma, except those treated with oral corticosteroid > therapy)
  • Cerebrospinal fluid leaks
  • Diabetics
  • Cochlear implant recipients > (pre and/or post implant)
  • Nephrotic Syndrome
  • Recipients of hematopoietic stem cell transplant (HSCT) at any age (4 doses)

High Risk individuals include:

  • those with asplenia, functional or anatomic
  • transplant recipients
  • complement, properdin or factor D deficiencies

Medically high risk individuals 2 years and older including:

  • Cerebrospinal fluid leak or hydrocephaly
  • Functional or anatomic asplenia
  • Congenital immunodeficiency states (e.g., complement, properdin, factor D deficiency, primary antibody deficiencies)
  • Hematopoietic stem cell transplant recipient
  • Cochlear transplant candidate or recipient
  • Solid organ transplant candidate or recipient
  • Islet cell transplant candidate or recipient

Susceptible high risk individuals include:

  • those with cystic fibrosis
  • long term acetylsalicylic > acid therapy
  • immunocompromised individuals as determined by their specialist

Individuals born since Jan.1, 1993 that are susceptible

No

MB

Children 24 - 59 months with high-risk medical conditions as per the CIG and NACI statements

Individuals (2 months or older) with high-risk medical conditions as per the CIG and NACI statements

Individuals 2 – 55 years of age with high-risk medical conditions as per the CIG and NACI statements

Individuals with high-risk medical conditions and their household contacts as per the CIG and NACI statements

Females 9 to ≤ 17 year olds with increased risk of getting HPV, as determined by a health care provider, including:

  • Early onset of sexual activity
  • Multiple sexual partners
  • A previous STI
  • Adolescent pregnancy
  • An immune system weakened by disease or medical treatment
  • Previous abnormal pap tests
  • Family-history of HPV-associated cancers

ON

All children under 5 years of age with the following medical conditions:

  • Chronic respiratory disease (excluding asthma, except those treated with high-dose corticosteroid therapy)
  • Chronic cardiac disease
  • Chronic liver disease (including hepatitis B and C, and hepatic cirrhosis due to any cause)
  • Chronic renal disease, including nephrotic syndrome
  • Diabetes mellitus
  • Asplenia (functional or anatomic), splenic dysfunction, sickle-cell disease and other sickle cell haemoglobinopathies
  • Chronic neurologic condition that may impair the clearance of oral secretions
  • Chronic cerebrospinal fluid leak
  • Primary immune deficiency
  • Congenital immunodeficiency involving any part of the immune system, including B-lymphocytes (humoral) immunity, T-lymphocytes (cell) mediated immunity, complement system (properdin or factor D deficiencies), or phagocytic functions
  • HIV infection
  • Other conditions associated with immunosuppression (e.g. malignant neoplasms, including leukemia and lymphoma)
  • Immunosuppressive therapy, including use of long term systemic corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, certain anti-rheumatic drugs and other immunosuppressive therapy
  • Hematopoietic stem cell transplant (candidate or recipient)
  • Solid organ or islet cell transplant (candidate or recipient)
  • Cochlear implant recipients (pre/post implant)

Close contacts of a case of serogroup C invasive Meningococcal disease; close contacts of a case include:

  1. Individuals with functional or anatomic asplenia (vaccine should be given at least 10-14 days before splenectomy).
  2. Individuals with complement, properdin or factor D deficiency.
  3. HIV positive individuals, close contacts of a case of serogroup C invasive Meningococcal disease, anyone who has come into direct contact (including respiratory droplets) with a case, including but not limited to family/household, school/work colleagues, and social contacts

Individuals 2-55 years of age with high-risk medical conditions as per the CIG and NACI statements

High Risk Criteria for Varicella Vaccine:

1. Children and adolescents given chronic salicylic acid therapy (consider stopping treatment for 6 weeks after vaccination, see product monograph).

2. People with cystic fibrosis.

3. Susceptible household contacts of immunocompromised persons.

4. Immunocompromised individuals

 

QC

Children aged between 5 and 17 years old with medical conditions that increase the risk of invasive pneumococcal infections:

  • Anatomic or functional asplenia (splenectomy, sickle cell anemia)
  • Immunosuppression
  • Cochlear implant recipients
  • Chronic renal deficiency or nephrotic symptoms
  • High prematurity (< 32 weeks or weight <1500 g at born), risk in the first year of life
  • Chronic disease or condition:
  • Pulmonary (chronic obstructive disease, cystic fibrosis, emphysema). Asthma has not been associated with high risk of invasive infections unless combined with chronic bronchitis, emphysema or long-term systemic cortisone therapy
  • Cardiac (cardiac deficiency, cardiomyopathy, cardiac cyanosis)
  • Hepatic (cirrhosis, alcoholism)
  • Diabetic
  • Chronic cerebrospinal fluid leak
  • Medical condition that may impair clearance of oral secretions or increase their risk of aspiration (cognitive impairment, spinal cord injury, seizure disorder, neuromuscular disorders)
  • Homeless
  • Actual and regular use of injected or inhaled hard drugs with decreasing health condition or precarious living conditions
  • Individuals 18 years old and over with specific health conditions (anatomic or functional asplenia or immunosuppression)

Children ≥ 2 mths who had close contacts with a case of serogroup C invasive Meningococcal disease

Children ≥ 2 months at high risk:

  • Functional or anatomic asplenia (exp. splenectomy, sickle cell anemia)
  • Complement, properdin or factor D deficiency
  • Congenital antibody deficiency
  • Close contact of a case of serogroup A, Y or W135 Meningococcal disease

Individuals 1 year and older receptive to varicella

After age 50, it is preferable to give the herpes zoster vaccine

Females 18 to 26 years old immunocompromised or HIV infected

NB

Children, with health conditions that place them at greater risk of IPD:

  • Chronic liver disease (hepatitis B, hepatitis C, cirrhosis due to any cause)
  • Chronic renal and dialysis
  • Splenic disorders, functional asplenia or splenectomy
  • Immunosuppression/ immunosuppressive therapy/immune disorders (B-lymphocyte (humoral) immunity T-lymphocyte (cell) mediated immunity or phagocytic functions deficiencies
  • Bone marrow/stem cell or islet transplant (pre and post procedure)
  • Organ transplant (pre and post procedure)
  • Cerebral fluid leak
  • Heart disease or stroke or pulmonary disorders (individuals with asthma are excluded)
  • Complement, properdin, or factor D deficiency
  • Diabetes mellitus and other metabolic diseases
  • Sickle cell disease and anaemia, hemoglobinopathy
  • Cancers
  • HIV (acute or chronic cases, contacts)
  • Cochlear implant (pre and post procedure)

Individuals with the following conditions:

  • Splenic disorders (functional  asplenia or splenectomy)
  • Complement, properdin, or factor D deficiency
Close contacts of a case

Individuals with the following conditions:

  • Splenic disorders (functional  asplenia or splenectomy)
  • Complement, properdin, or factor D deficiency

Close contacts of a case

Individuals with the following conditions:

  • Chronic renal disease or dialysis
  • Splenic disorders (functional asplenia or splenectomy)
  • Pulmonary disorders (cystic fibrosis)
  • Malignant neoplasms including lymphoma and leukemia, HIV (if prerequisite condition allow)
  • Individuals given chronic salicylic acid therapy (if prerequisite condition allow)
 

NS

HIV infection, immunocompromising conditions (e.g. primary immunodeficiency, malignancies, immunosuppressive therapy, solid organ transplant, bone marrow/stem cell transplants, long term systemic corticosteroids, nephrotic syndrome)

High risk individuals include: those with functional or anatomic asplenia and persons with complement, properdin or factor D deficiency.

Children 2 months of age or older and adults with splenic disorders or complement, properdin, or factor D deficiencies, bone marrow/stem cell transplant

High risk groups include: splenic disorders, immunosuppression/ immunosuppressive therapy (when immunocompetent, as determined by an health care provider), bone marrow/stem cell or organ transplant

 

PE

  • Splenectomized patients
  • Individuals with decreased immunity due to sickle cell anemia or primary IgG deficiency
  • Cochlear implant recipients
  • All children up to age 59 mths who:
  • were born before 32 weeks gestation
  • fit the following diagnosis:
  • congenital immune deficiency
  • diseases associated with immunosuppressive therapy or radiation therapy (including malignant neoplasms, leukemias, lymphomas, and Hodgkin's disease) and solid organ transplantation
  • chronic renal insufficiency, including nephrotic syndrome
  • chronic cardiac disease (particularly cyanotic congenital heart disease and cardiac failure)
  • chronic pulmonary disease (excluding asthma, except those treated with high-dose oral corticosteroid therapy)
  • cerebrospinal fluid leaks
  • poorly controlled diabetes mellitus
  • Splenectomized patients
  • Individuals with decreased immunity due to sickle cell anemia or primary IgG deficiency
  • Cochlear implant recipients
  • Splenectomized patients
  • Individuals with decreased immunity due to sickle cell anemia or primary IgG deficiency
  • Cochlear implant recipients
  • Close contacts of cases

Routine immunization since 2000

 

NL

2 months to ≤ 5 years of age:

  • Aboriginal children (including First Nations, Inuit and Metis)
  • Cochlear implants (candidates and recipients)
  • Congenital or acquired asplenia, splenic dysfunction and sickle-cell disease
  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV infection
  • Immunosuppression (e.g., congenital immune deficiency, Hodgkin’s disease, lymphoma, multiple myeloma, leukemia and therapy with alkylating agents, antimetabolites, systemic corticosteroids or radiation therapy)
  • Chronic renal disease, including nephrotic syndrome
  • Chronic cardiac disease
  • Chronic pulmonary disease (excluding asthma unless treated with high-dose oral corticosteroid therapy)
  • Cerebrospinal fluid leaks
  • Poorly controlled diabetes mellitus
  • Chronic neurologic condition that may impair clearance of oral secretions.
  • Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humeral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions.
  • Chronic liver disease (including hepatitis B and C, and hepatic cirrhosis due to any cause).

6 to ≤ 16 years of age:

  • Congenital or acquired asplenia, including those with sickle-cell disease and other hemoglobinopathies (functional asplenia) and splenic dysfunction
  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV Infection

17 years and older:

  • Candidates/recipients of solid organ transplant (SOT)
  • Recipients of hematopoietic stem cell transplant (HSCT)
  • HIV Infection

Children > 2 months -10 years with the following conditions

  • Stem Cell Transplant (SCT)
  • Bone Marrow Transplant (MBT)
  • Functional or anatomic asplenia
  • Immunosuppressive therapy

High risk groups include:

  • Household and intimate social contacts of individuals with meningococcal disease
  • Individuals > 2 years with the following conditions:
  • Stem Cell Transplant (SCT)
  • Bone Marrow Transplant (MBT)
  • Pre or post splenectomy
  • Susceptible health care workers
  • Susceptible household contacts of immunocompromised people
  • Selected immuno-compromised individuals
 

NT

As per NACI recommendations

As per NACI recommendations

As per NACI recommendations

As per NACI recommendations

 

YT

Children 2-59 mths of age who are at high risk of pneumococcal disease due to:

  • Sickle cell disease
  • Immunosuppression related to disease (e.g. HIV, lymphoma, Hodgkin’s, multiple myeloma) or therapy (e.g. high dose, systemic steroids)
  • Receipt of hematopoietic stem cell transplant (HSCT)
  • Solid organ or islet cell transplant (candidate or recipient)
  • Chronic heart or lung disease (except asthma, unless management involves ongoing high dose oral corticosteroid therapy)
  • Chronic liver disease including cirrhosis, chronic hepatitis B, chronic hepatitis C
  • Chronic kidney disease
  • Diabetes
  • Cystic fibrosis
  • Chronic CSF leak
  • Cochlear implant, candidate or recipient
  • Anatomic or functional asplenia (children up to and including 16 years of age)
  • Chronic neurological conditions that may impair clearance of oral secretions
  • HIV positive individuals

Children 2 up to 19 years of age who have not previously received meningococcal C conjugate vaccine or who present a medical high risk condition, including:

  • Functional or anatomic asplenia
  • Complement, properdin, or factor D deficiencies
  • Hematopoietic stem cell transplant (HSCT)
  • Solid organ transplant (candidate or recipient)
  • Islet cell transplant (candidate or recipient)
  • Cochlear implant, or who will be receiving a cochlear implant

Individuals 2 years of age and older with the following conditions:

  • Functional or anatomic asplenia
  • Congenital immunodeficiency states including complement, properdin, or factor D deficiencies
  • Hematopoietic Stem Cell Transplant
  • Solid organ transplant (candidate or recipient)
  • Islet cell transplant (candidate or recipient)
  • High risk ≥ 2 years, and contacts (≥ 2 years) of cases (serotypes A, Y and W-135)

The varicella vaccine is recommended for:

  • Susceptible older children and adolescents
  • Susceptible women of childbearing age (not during pregnancy)
  • Susceptible health care workers
  • Susceptible household contacts of immunocompromised people
  • Susceptible adults who may be exposed occupationally to varicella
  • Other susceptible adults, especially new immigrants from tropical climates
  • Children and adolescents given chronic salicylic acid therapy
  • People with cystic fibrosis
  • Immunocompromised individuals
 

NU

Routine infant immunization

  • Contacts of cases
  • Certain students or athletes < 25 years, if not previously vaccinated
  • Other high risk individuals including those with asplenia, certain immunodeficiencies, and cochlear implants

Contacts of cases (A, Y and W135) ≥ 2 years

Women who test negative at prenatal screen

 

http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/fluvacc-eng.php

Государственное финансирование вакцинации против гриппа по провинциям / территориям
(По состоянию на сентябрь 2013 года)

Target BC YK AB NT NU SK MB ON QC NB NS NL PE

Original Source: Canadian Pharmacists Association, 2009

1 Police, firefighters, ambulance personnel, and correctional officers
2 The flu vaccine is available free of charge to all residents; however, public education campaigns focus attention on immunizing high risk groups.
3 Vaccine is available free of charge to individuals aged 6 mths or older who live, work or attend school in Alberta/Ontario.
4 Vaccine is free of charge to anyone who requests it
5 For the year 2012-2013, the vaccine is available free of charge to all Manitoba residents aged 6 months or older; however, public education campaigns focus attention on immunizing high risk groups.
6 Vaccine is free of charge to all residents of PEI; however, administration of the vaccine is not covered except for those noted above

The following priority groups are recommended for annual influenza vaccination programs by the National Advisory Committee on Immunization (NACI): people at high risk for influenza-related complications, those capable of transmitting influenza to individuals at high risk for complications, and those who provide essential community services. As significant morbidity and societal costs are associated with seasonal interpandemic influenza illness and its complications occurring in healthy children age ≥ 2 years and healthy adults, healthy children age ≥ 2 years and adults should also be encouraged to receive the annual influenza vaccine. For the full NACI recommendations for influenza immunization go to: Statement on Seasonal Influenza Vaccine for 2012–2013

Universal vaccination

 
checkmark2
checkmark3
checkmark4
checkmark4
checkmark2
checkmark5
checkmark3
   
checkmark2
 
checkmark6

Special considerations for the 2013-2014 season

▪ Persons with morbid obesity
(BMI ≥ 40)

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Aboriginal peoples

checkmark
         
checkmark
   
checkmark
checkmark
checkmark
 

▪ Healthy children 6 to 59 months of age

           
checkmark
   
checkmark
checkmark
checkmark
checkmark

Pregnant women in their 3rd trimester, expecting to deliver in influenza season

checkmark
         
checkmark
 
checkmark
 
checkmark
 
checkmark

Pregnant women, any trimester

           
checkmark
   
checkmark
checkmark
checkmark
checkmark

Children 6 months to 23 months

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
checkmark

Persons 18 years and older

                         

Persons 50-64 years

                         

Persons 60 years and older

               
checkmark
   
checkmark
 

Persons 65 years and older

checkmark
         
checkmark
   
checkmark
checkmark
 
checkmark

Residents of nursing homes or chronic care facilities

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
checkmark

Health care workers

checkmark
         
checkmark
 
checkmark
 
checkmark
checkmark
checkmark

Children and adolescents on long-term ASA

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

Persons on long-term ASA (e.g. RA patients)

           
checkmark
     
checkmark
checkmark
 

Household contacts of people at high-risk

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

Persons with weakened immune systems

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

Essential community services: first responders

checkmark 1
         
checkmark
     
checkmark
checkmark
 

Persons at risk travelling to destinations where influenza is likely circulating

                         

Persons in direct contact with poultry infected with avian influenza during culling operations

checkmark
             
checkmark
   
checkmark
 

Adults and children with chronic conditions severe enough to require regular medical follow-up or hospital care such as:

▪ Cardiac disease

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Pulmonary disease

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Asthma

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Diabetes

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Renal disease

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

▪ Liver disease

checkmark
         
checkmark
 
checkmark
 
checkmark
checkmark
 

▪ Anaemia or hemoglobinopathy

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

HIV patients

checkmark
         
checkmark
 
checkmark
 
checkmark
checkmark
 

▪ Immunosuppression, cancer

checkmark
         
checkmark
 
checkmark
checkmark
checkmark
checkmark
 

http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-eng.php
Вакцинация конкретных групп населения

http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-02-eng.php

Иммунизация взрослых

Рекомендации по плановой иммунизации здоровых взрослых людей с низким риском
Vaccine Recommendations for routine immunization
Diphtheria Tetanus Primary series for previously unimmunized adults
Booster dose every 10 years
Herpes zoster (shingles) 60 years of age and older - 1 dose
50 to 59 years of age - may be given 1 dose
HPV Women up to and including 26 years of age - bivalent (HPV2) or quadrivalent (HPV4) vaccine
Men up to and including 26 years of age -HPV4 vaccine
Measles Mumps Susceptible adults born in or after 1970 - 1 dose
Born before 1970 - consider immune
Meningococcal conjugate Adults up to and including 24 years of age not immunized in adolescence - 1 dose
Pertussis One dose of acellular pertussis-containing vaccine (Tdap) in adulthood
Adults who will be in close contact with young infants should be immunized as early as possible
Pneumococcal 23-valent polysaccharide (Pneu-P-23) 65 years of age and older - 1 dose
Polio Primary series for previously unimmunized adults when a primary series of tetanus and diphtheria toxoid-containing vaccine is being given or with routine tetanus and diphtheria-toxoid containing vaccine booster doses
Rubella Susceptible adults - 1 dose
If vaccine is indicated, pregnant women should be immunized after delivery
Varicella (chickenpox) Susceptible adults up to and including 49 years of age - 2 doses; if previously received 1 dose should receive a second dose
Known seronegative adults 50 years of age and older - 2 doses - routine testing is not advised


Рекомендации по иммунизации взрослых людей для конкретных ситуаций риска
Vaccine Recommendations for risk situations

Bacille Calmette-Guérin (BCG)

Consider use for adults:

  • who may be repeatedly exposed to persons with untreated, inadequately treated or drug-resistant active tuberculosis (TB) in conditions where protective measures against infection are not feasible and if early identification and treatment of latent TB infection are not available
  • who are long‑term travellers to high prevalence countries (in exceptional circumstances as noted above)

Cholera and travellers' diarrhea

Consider use for cholera prevention in adult travellers to cholera-endemic area(s) at high-risk of exposure, including those with occupational risk for exposure (e.g., health care or humanitarian workers in endemic countries)

Consider use for prevention of travellers' diarrhea in adults:

  • with chronic diseases at risk for complications
  • at increased risk of acquiring travellers' diarrhea
  • who are immunosuppressed

Haemophilus influenzae type b (Hib)

Recommended for adults with increased risk of invasive Hib disease:

  • congenital immunodeficiencies
  • malignant hematologic disorders
  • HIV
  • anatomic or functional asplenia
  • all transplant recipients
  • cochlear implant recipients

Following HSCT adults should receive 3 doses of Hib vaccine at least 4 weeks apart starting 6 to 12 months post-transplant

Hepatitis A

Recommended for adults:

  • travelling to hepatitis A (HA) endemic areas
  • who are immigrants from HA endemic areas
  • who are household or close contacts of children adopted from HA endemic countries
  • in communities or populations at risk of outbreaks or in which HA is highly endemic
  • who are household or close contacts of proven or suspected cases of HA
  • with occupational or lifestyle risk for exposure
  • with chronic liver disease from any cause, including those infected with hepatitis C
  • with hemophilia A or B receiving plasma-derived replacement clotting factors
  • for post-exposure or outbreak management

Hepatitis B

Recommended for adults:

  • who have immigrated to Canada from areas where there is a high prevalence of HB
  • who are household or sexual contacts of acute hepatitis B (HB) cases and HB carriers, including close contacts of children adopted from HB endemic countries if the adopted child is HBsAg positive
  • with occupational or lifestyle risk for exposure
  • travelling to HB endemic areas
  • in communities/populations in which HB is highly endemic
  • who are residents of institutions for the developmentally challenged or inmates of correctional facilities
  • with chronic liver disease, including those infected with hepatitis C
  • with chronic renal disease, including chronic dialysis
  • hemophiliacs and other people who receive repeated infusions of blood or blood products
  • who have undergone hematopoietic stem cell transplantation or are awaiting solid organ transplant
  • who have congenital immunodeficiencies
  • who are HIV-infected
  • for post-exposure management

HPV

May be given to men and women 27 years of age and older at ongoing risk of exposure*

Influenza

Recommended annually for adults:

  • at high risk of influenza-related complications
  • capable of transmitting influenza to individuals at high risk
  • who provide essential community services
  • in direct contact during culling operations with poultry infected with avian influenza

Japanese encephalitis

Recommended for adults:

  • with occupational risk for exposure
  • travelling to endemic area(s) during transmission season with specified exposure risks

Booster dose 12 months after primary immunization for persons at continuous risk

Measles Mumps

Recommended for adults born in or after 1970:

  • If susceptible and at increased risk of exposure (travellers to destinations outside of North America, health care workers, students in post-secondary educational settings, and military personnel) - 2 doses, at least 4 weeks apart.

Recommended for adults born before 1970 if:

  • non-immune military personnel or health care workers - 2 doses, at least 4 weeks apart
  • non-immune travellers - 1 dose
  • non-immune students - consider 1 dose

Recommended for early post-exposure management of measles

Meningococcal quadrivalent conjugate

Recommended for adults:

  • with occupational risk for exposure (i.e., laboratory workers and the military)
  • who are travellers for whom meningococcal vaccine is recommended or required, including travellers to sub-Saharan African and pilgrims to the Hajj in Mecca, Saudi Arabia
  • at high risk of meningococcal disease due to medical conditions:
    • anatomic or functional asplenia (including sickle cell disease)
    • congenital complement, properdin, factor D or primary antibody deficiencies
    • acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab consider use for HIV-infected adults
  • who are close contacts of a case of invasive meningococcal disease caused by a vaccine preventable serogroup
  • for management of an outbreak caused by a vaccine preventable serogroup

Booster doses every 5 years if risk is ongoing

Pneumococcal 23-valent polysaccharide (Pneu-P-23)

Recommended for adults:

  • who are residents of long-term care facilities
  • who are at increased risk of invasive pneumococcal disease (IPD) due to lifestyle factors:
    • persons with alcoholism
    • smokers
    • persons who are homeless
  • who are at high risk of IPD but without immunosuppression. Persons with:
    • asthma requiring regular medical care
    • chronic cerebral spinal fluid (CSF) leak
    • chronic neurologic condition that may impair clearance of oral secretions
    • cochlear implants (including those who are to receive implants)
    • chronic cardiac or pulmonary disease
    • diabetes mellitus
    • chronic kidney disease, including nephrotic syndrome
    • chronic liver disease (including hepatic cirrhosis due to any cause)
  • who are at high risk of IPD AND are immunosuppressed. These persons should receive Pneu-C-13 vaccine followed by Pneu-P-23 vaccine eight weeks later. Persons with:
    • asplenia (functional or anatomic)
    • sickle cell disease or other hemoglobinopathies
    • congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
    • HIV infection
    • immunosuppressive therapy including use of long‑term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, and biologic and non-biologic immunosuppressive therapies for rheumatologic and other inflammatory diseases
    • malignant neoplasms including leukemia and lymphoma
    • solid organ or islet cell transplant (candidate or recipient).

Consider for individuals who use illicit drugs

One lifetime booster dose for adults at highest risk of IPD.

Pneumococcal 13-valent conjugate (Pneu-C-13)

The following adults should receive 1 dose of Pneu-C-13 vaccine followed 8 weeks later by 1 dose of Pneu-P-23 vaccine. Adults with:

  • asplenia (functional or anatomic)
  • sickle cell disease or other hemoglobinopathies
  • congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
  • HIV infection
  • immunosuppressive therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, and biologic and non-biologic immunosuppressive therapies for rheumatologic and other inflammatory diseases
  • malignant neoplasms including leukemia and lymphoma
  • solid organ or islet cell transplant (candidate or recipient)

Following HSCT, adults should receive 3 doses of Pneu-C-13 vaccine at least 4 weeks apart followed by a dose of Pneu-P-23 vaccine 6 to 12 months after the last Pneu-C-13 dose (refer to Immunization of Immunocompromised of Persons in Part 3 for additional information)

Polio

Priority for adults who are:

  • travelling to, or receiving travellers from, areas where poliovirus is known or suspected to be circulating
  • health care workers who have close contact with patients who might be excreting wild type or vaccine type poliovirus
  • members of communities or specific population groups with disease caused by polio
  • people who come in close contact with those who may be excreting poliovirus (e.g., people working with refugees, or the military and people on humanitarian missions in endemic countries)
  • laboratory workers handling specimens that may contain poliovirus
  • family or close contacts of internationally adopted infants who may have been or will be vaccinated with OPV vaccine

For previously unimmunized adults - primary series of IPV-containing vaccine

For previously immunized adults - one lifetime booster dose of IPV-containing vaccine

Rabies (pre-exposure prophylaxis)

Recommended for adults:

  • with occupational risk of exposure
  • with lifestyle risk of exposure
  • travelling to high‑risk areas with specified exposure risks

Booster doses if required

Smallpox

Recommended for adults with occupational risk of exposure

Typhoid

Recommended for adults:

  • travelling to endemic area(s) with specified exposure risks
  • who have ongoing household or intimate exposure to an S. typhi carrier
  • with occupational risk of exposure

Booster doses if at ongoing risk

Yellow fever

Recommended for adults:

  • less than 60 years of age travelling to areas where there is evidence of yellow fever transmission or if required for foreign travel
  • with occupational risk of exposure

Consider use for adults aged 60 years and over travelling to areas where risk of yellow fever is the highest

Re-immunization recommended every 10 years for immunocompetent people, if indicated


http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-04-eng.php

Резюме рекомендаций для иммунизации восприимчивых беременных женщин или кормящих матерей
(Вакцины, перечислены в алфавитном порядке.)
Vaccine Use in pregnancy Use in breastfeeding Comments
1 - when benefits outweigh risks
Inactivated vaccines
Cholera and travellers' diarrhea Use if indicated in high risk situations1 Use if indicated
  • No data on use during pregnancy or breastfeeding
Hepatitis A Use if indicated in high risk situations1 Use if indicated
  • No data on efficacy and safety during pregnancy Hep A vaccine should be considered for pregnant women when potential benefits outweigh risks such as for post-exposure prophylaxis or for travel to high risk endemic area
Hepatitis B Use if indicated1 Use if indicated
  • HB vaccine can be used safely in pregnancy and during breastfeeding
Human papillomavirus (HPV) Currently not recommended Use if indicated
  • Limited data on use during pregnancy and breastfeeding
Influenza (inactivated) Recommended Recommended
Japanese encephalitis Use if indicated in high risk situations1 Use if indicated in high risk situations1
  • No data on safety or efficacy during pregnancy or breastfeeding
Meningococcal conjugate Use if indicated1 Use if indicated
  • No data on use during pregnancy. Should be considered for pregnant women in circumstances such as travel to a high -risk area; post-exposure prophylaxis against a vaccine preventable strain; or during an outbreak.
  • Refer to Meningococcal Vaccine in Part 4 for a listing of high risk conditions.
Pneumococcal conjugate 13-valent (Pneu-C-13) Use if indicated for high risk conditions Use if indicated for high risk conditions
  • No data on use during pregnancy
  • Refer to Pneumococcal Vaccine in Part 4 for a listing of high risk conditions.
Pneumococcal polysaccharide (Pneu-P-23) Use if indicated for high risk conditions Use if indicated for high risk conditions
Polio (inactivated) Use if immediate protection needed and at increased risk of exposure to wild poliovirus Use if indicated
  • Lack of evidence of risk to fetus or pregnancy
Rabies Use if indicated for post-exposure prophylaxis

Delay pre-exposure immunization unless substantial risk of exposure
Use if indicated
Tetanus-reduced diphtheria (Td) Use if indicated Use if indicated
  • Lack of evidence of risk to fetus or pregnancy
Tetanus-reduced diphtheria-reduced acellular pertussis (Tdap) Consider use in second half of pregnancy if pertussis is circulating locally and Tdap vaccine not previously received in adulthood Recommended - administer as early as possible post-partum if Tdap vaccine not previously received in adulthood
  • Lack of evidence of risk to fetus or pregnancy
  • Use Tdap vaccine during pregnancy is currently under review by NACI
Typhoid (inactivated) Use if indicated in high risk situations1 Use if indicated
  • No data on use during pregnancy or breastfeeding
Live vaccines
Bacille Calmette-Guérin (BCG) Contraindicated Generally should not be used

May be considered in high risk situations
  • Lack of evidence of risk to fetus
  • No data on use in pregnancy or breastfeeding
Influenza (intranasal) Should not be used Use if indicated
  • Live attenuated influenza vaccine has a similar or lower efficacy than inactivated influenza vaccine in adults; inactivated influenza vaccine is preferred if chronic health condition.
  • No data on use during pregnancy
Measles-mumps-rubella Generally contraindicated

Immunize rubella-susceptible women immediately post-partum
Recommended if not immune
  • No known fetal effects; theoretical risk
  • Inadvertent immunization is not a reason for pregnancy termination
Smallpox Generally contraindicated

Consider use in high risk situations (e.g., post-exposure, outbreak)1
Generally should not be used

May be considered in high risk situations (e.g., post-exposure, outbreak) 1
  • May cause fetal infection
  • Suspend breastfeeding until scab falls off
  • Close contacts who are vaccinated should be isolated from pregnant women as well as lactating women and their newborn until scab falls off
Typhoid (oral) Contraindicated Use inactivated vaccine if indicated
  • Although there are no data, it is reasonable to assume that either Typh-I vaccine could be used safely in lactating mothers.
Varicella Contraindicated

Immunize varicella-susceptible women immediately post-partum
Recommended if not immune
  • No known fetal effects; theoretical risk
  • Inadvertent immunization is not reason for pregnancy termination
Yellow fever Generally contraindicated unless travel to area at high risk of transmission is unavoidable and high level of mosquito protection is not feasible Generally contraindicated unless travel to area at high risk of transmission is unavoidable and high level of mosquito protection is not feasible
  • Seroconversion rates lower during pregnancy; post-immunization serology recommended
  • Limited data on fetal safety
  • Inadvertent immunization is not reason for pregnancy termination
  • Probable transmission of vaccine strain of yellow fever virus to the infant via breastfeeding has been reported










Список статей:

• NEW! Календарь прививок Российской Федерации, 2014 год
• Календарь прививок РФ в предыдущие годы (2009, 2001, 1998 годы)
• Календарь прививок СССР
• Календарь прививок РФ (региональный, г. Москва), 2011 год
• Календарь прививок РФ (региональный, Оренбургская область), 2013 год
• Календарь прививок РФ (региональный, Свердловская область), 2011 год
• Календарь прививок РФ (региональный, Ханты-Мансийского автономного округа-Югры), 2012 год
• Календарь прививок республики Беларусь, 2012 год
• Календарь прививок Украины, 2011 год
• Календарь прививок Республики Казахстан, 2013 год
• Календарь прививок Республики Молдова, 2011 год
• Календарь прививок Республики Узбекистан, 2008 год
• Календарь прививок Австралии, 2013 год
• Календарь прививок Австрии, 2013 год
• Календарь прививок Бельгии
• Календарь прививок Великобритании, 2013 год
• Календарь прививок Германии, 2013 год
• Календарь прививок Голландии, 2013 год
• Календарь прививок Индии
• Календарь прививок Италии 2012-2014
• Календарь прививок Канады, 2013 год
• Календарь прививок Польши, 2013 год
• NEW! Календарь прививок США, 2014 год, 2013 год, 2010 год
• Календарь прививок Швейцарии, 2013 год

 ▲ 

 
 
        
Посещений: 3728154